SCHEMBL292931

SCHEMBL292931

CCCCN(CCC)C(N)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 6/20 0.52
CA9 Q16790 6/20 0.52
CA1 P00915 6/20 0.52
MMP1 P03956 1/20 0.48
MMP2 P08253 1/20 0.48
MMP3 P08254 1/20 0.48
MMP8 P22894 1/20 0.48
CA2 P00918 5/20 0.44
SIGMAR1 Q99720 2/20 0.43
ALDH1A1 P00352 2/20 0.41
ALDH2 P05091 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
HPGD P15428 2/20 0.39
TP53 P04637 1/20 0.38
GAA P10253 1/20 0.36
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL42636 0.95 CA1 (0.56) CA12CA9CA1MMP1MMP2
SCHEMBL55496 0.95 CA1 (0.56) CA12CA9CA1MMP1MMP2
SCHEMBL4370605 0.93 CA12 (0.45) CA12CA9CA1MMP1MMP2
Butane SCHEMBL9632378 0.93 CA1 (0.54) CA12CA9CA1MMP1MMP2
Hydrochloric Acid SCHEMBL27402428 0.93 CA1 (0.54) CA12CA9CA1MMP1MMP2
SCHEMBL25278115 0.91 CA12 (0.47) CA12CA9CA1MMP1MMP2
SCHEMBL25277759 0.91 CA12 (0.47) CA12CA9CA1MMP1MMP2
SCHEMBL25277907 0.91 CA12 (0.47) CA12CA9CA1MMP1MMP2
SCHEMBL30433893 0.91 CA12 (0.47) CA12CA9CA1MMP1MMP2
SCHEMBL25227050 0.91 CA12 (0.47) CA12CA9CA1MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
CN-118382612-A Method for producing blocked isocyanate compound and method for producing isocyanate compound 旭化成株式会社 2024-07-23 CN disclosed
WO-2023106377-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND 旭化成株式会社 2023-06-15 WO disclosed
CN-102575137-B adhesive resin composition for silicon wafer ADEKA CORP 2014-11-26 CN disclosed
CN-103261284-B Masterbatch-type latent curing agent for epoxy resin, and epoxy resin composition using same ADEKA CORP 2014-07-23 CN disclosed
US-8158790-B2 Cyclic amine compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-04-17 US disclosed
EP-2036896-B1 CYCLIC AMINE COMPOUND DAIICHI SANKYO CO LTD (JP) 2012-03-14 EP disclosed
US-20090286807-A1 CYCLIC AMINE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-19 US disclosed
EP-2036896-A1 CYCLIC AMINE COMPOUND Daiichi Sankyo Company, Limited (JP) 2009-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286807-A1 CYCLIC AMINE COMPOUND HRH3, HRH4, H1-0 CA12 4320/4885CA9 3870/4885CA1 4685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.